Peptide News & Updates
Regulatory changes, new studies and approved-drug updates for the peptides this site covers, summarized in plain English with links to every source.
- FDA & WADA actions
- New studies, summarized
- Every update linked to its source
Latest Updates
Newest first. Tap a type to filter.
FDA Sends a Peptide “Interim Access Policy” to the White House
A policy that could let pharmacies compound some peptides, reportedly including BPC-157, is now under White House review. Its text isn't public.
Unapproved Retatrutide Bought Online: What Three New Journal Articles Report
Three October journal pieces examine retatrutide sold outside approved channels: self-reported effects, product testing and a hospital case.
Peptide Research Roundup: New Papers, October 3–16, 2026
Four new papers: a KPV macrophage study, a BPC-157 and TB-500 case review, a MOTS-c perspective and a Lancet retatrutide commentary.
Report: Administration Drafting a Stopgap to Allow Sales of Some Unapproved Peptides
A reported draft plan would let some pharmacies compound restricted peptides before FDA finishes its rules. Nothing has been announced.
“Research Use Only” Isn’t a Shield: FDA Warning Letters and the Gray-Market Peptide Trade
Five sellers got FDA warning letters: dosing guides and calculators outweighed their “research use only” labels.
GLP-1 Pipeline Note: Orforglipron’s Blood-Pressure Trial and CagriSema’s Pending Decision
A first-of-its-kind blood-pressure trial design for a GLP-1 pill, and CagriSema still awaiting an FDA decision.
WADA’s 2027 Prohibited List: GLP-1 Drugs Stay Permitted, Peptide Rules Carry Over
GLP-1 drugs stay off the banned list for 2027; peptide categories carry over unchanged in the published summaries.
Peptide Research Roundup: New Studies, Late August to Early October 2026
Six new papers: a critical BPC-157 review, thymosin beta-4 in colitis models, a GHK-Cu evidence map, and new mitochondrial-peptide work.
FDA Advisers Back Six Peptides for Compounding: What the July Vote Did and Didn’t Change
Advisers recommended six peptides for the 503A Bulks List by narrow margins. Nothing is legal to compound until FDA finishes rulemaking.
Retatrutide’s Three Phase 3 Readouts and the First Oral Non-Peptide GLP-1: A 2026 Update
Three Phase 3 readouts for the investigational triple agonist retatrutide, and FDA approval of orforglipron, a GLP-1 pill that isn’t a peptide.
Twelve Peptides Leave FDA’s Category 2 List: A Recap of the April 2026 Change
Twelve peptides came off FDA’s “significant safety risk” list in April. That opened a review, not a green light.
What We Cover Here
Regulatory Watch
FDA compounding decisions, advisory committee votes and anti-doping rules, explained in plain terms with what changed and what didn’t.
Research Roundups
New peer-reviewed studies on the compounds this site covers, each with the model used, what was reported and where the study stops.
Approved-Drug Updates
Trial readouts and approvals for prescription peptides and related drugs, reported from company and regulatory sources.
Get New Updates in Your Inbox
One short email when a regulatory change or a notable new study is published. No spam, and you can unsubscribe anytime.
Research summaries and updates only. We never share your email.